Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03486990 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT03486990 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 23 participants.
The verdict
NCT03486990, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study is to characterize the safety and tolerability of an investigational drug called TIMP-GLIA when either one or two intravenous doses are given to subjects with celiac disease. The way the body reacts to TIMP-GLIA is being checked by laboratory tests of the blood and urine, and study subject health will also be monitored by vital signs such as blood pressure, electrocardiogram (ECG), and physical examination.
Interventions
- DRUG TIMP-GLIA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-01-23 |
| Est. Completion | 2019-07-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03486990
The ClinicalTrials.gov registry entry for NCT03486990 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TIMP-GLIA is the first listed.
NCT03486990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03486990 about?
NCT03486990 is a clinical study titled "Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease". This study is to characterize the safety and tolerability of an investigational drug called TIMP-GLIA when either one or two intravenous doses are given to subjects with celiac disease. The way the body reacts to TIMP-GLIA is being checked by laboratory tests of the blood and urine, and study subjec...
What is the current status of trial NCT03486990?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2018-01-23. Estimated completion is 2019-07-22.
What interventions are being tested in trial NCT03486990?
The interventions under investigation include: TIMP-GLIA (DRUG).
Who is sponsoring clinical trial NCT03486990?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.